Advertisements



Bristol-Myers can be "a sweet pill" for investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 12th, 2019

Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors

Wall Street has soured on the deal for Celgene, but Bristol-Myers has one of the lowest valuations in the drug sector and could itself become a takeover target.....»»

Category: topSource: barronsJan 13th, 2019

Here"s What Starboard Might Be Planning for Papa John"s and Bristol-Myers

The hedge fund has a history in both restaurants and in health care. It isn’t clear what Starboard CEO Jeff Smith plans this time, but investors should take note......»»

Category: topSource: barronsFeb 5th, 2019

Barron"s Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

This weekend's Barron's cover story reveals the results of the Barron's 2019 Investment Roundtable. Other featured articles examine safe dividend growth stocks and the best stock funds for risky markets. read more.....»»

Category: blogSource: benzingaJan 13th, 2019

Should Investors Like Bristol-Myers" Buyout of Celgene?

The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual......»»

Category: topSource: foxnewsJan 7th, 2019

Celgene Investors Should Take the Money and Run

With Celgene stock trading 25% higher after Bristol-Myers Squibb made a $74 billion acquisition offer, Celgene investors probably shouldn’t wait around to see if the deal closes......»»

Category: topSource: barronsJan 4th, 2019

Celgene shareholders should sell now, Leerink says

Bristol-Myers Squibb Co.'s agreement to acquire Celgene Corp. is "an exit opportunity for Celgene shareholders," Leerink analysts wrote in a note to investors Thur.....»»

Category: topSource: marketwatchJan 3rd, 2019

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Category: topSource: reutersJul 27th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday......»»

Category: topSource: reuters11 hr. 21 min. ago

Bristol-Myers says Opdivo-Yervoy combo shows ORR of 25% in CheckMate -650 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2019

Big option blocks in Bristol Myers Squibb as an expiring position is closed

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2019

Bristol-Myers" Sprycel Gets European Nod for Label Expansion

Zacks.....»»

Category: topSource: redinewsFeb 13th, 2019

Bristol-Myers Squibb Becomes #172 Most Shorted S&P 500 Component, Replacing National Oilwell Varco

Market News Video.....»»

Category: topSource: redinewsFeb 12th, 2019

Bristol-Myers says Opdivo-Yervoy combo showed improved ORR in Phase 3 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

EC approves Bristol-Myers" Sprycel, chemotherapy for Ph+ ALL

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

AT&T"s 5G act bad for consumers/investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 9th, 2019

Investors should buy the BB&T/SunTrust deal, not the trend, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 9th, 2019

Wabtec looks cheap, attractive to some investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 9th, 2019

Trump Drug-Prices Plan Could Hit 2 Pharma Stocks

Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse......»»

Category: topSource: barronsFeb 7th, 2019